Lancashire and South Cumbria
Formulary
Formulary
11 Eye
11-08-02 Subfoveal choroidal neovascularisation
| Aflibercept |
|
Formulary
|
Solution for intravitreal injection pre-filled syringe 40mg/mL Biosimilars of aflibercept are now available. Biosimilars should be considered first line when Aflibercept is prescribed. |
 LSCMMG: Opthalmology Macular Pathways MHRA: EYLEA 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion NICE TA346: Aflibercept for treating diabetic macular oedema NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion NICE TA486: Aflibercept for treating choroidal neovascularisation |
|
| Aflibercept 8mg in 0.07ml inj |
|
Formulary
|
Eylea 114.3 mg/ml solution for injection |
|
LSCMMG: Opthalmology Macular Pathways NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration NICE TA346: Aflibercept for treating diabetic macular oedema NICE TSID10590: High-dose aflibercept for treating wet age-related macular degeneration |
|
|
| Brolucizumab Beovu® |
|
Formulary
|
Solution for intravitreal injection 19.8mg/0.165ml |
|
LSCMMG: Opthalmology Macular Pathways MHRA: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals NICE TA672: Brolucizumab for treating wet age-related macular degeneration NICE TA820: Brolucizumab for treating diabetic macular oedema |
|
|
| Faricimab Vabysmo® |
|
Formulary
|
Solution for intravitreal injection 120 mg/mL |
|
LSCMMG: Opthalmology Macular Pathways NICE TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion NICE TA799: Faricimab for treating diabetic macular oedema NICE TA800: Faricimab for treating wet age-related macular degeneration |
|
|
| Ranibizumab |
|
Formulary
|
Solution for intravitreal injection 10mg/mL Ranibizumab biosimilars - |
|
LSCMMG: Opthalmology Macular Pathways NICE NG242: Diabetic retinopathy: management and monitoring NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration NICE TA274: Ranibizumab for treating diabetic macular oedema NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal) |
|
|
Byooviz, Ongavia, Rimmyrah and Ximluci | Bevacizumab gamma |
|
Formulary
|
|
NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration |
|
|
| Pegaptanib |
|
Formulary
|
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
|
Links
- Biosimilars policy statement
- Corneal superficial injury (CKS)
- Does the dose of intravenous fluorescein sodium need to be adjusted in renal impairment or renal replacement therapy?
- Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Opthalmology Macular Pathways
- LSCMMG: Opthalmology Macular Pathways
- LSCMMG: Opthalmology Macular Pathways
- LSCMMG: Opthalmology Macular Pathways
- LSCMMG: Opthalmology Macular Pathways
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update April 2016: Aflibercept (Zaltrap): minimising the risk of osteonecrosis of the jaw
- MHRA Drug Safety update Jan 2022: Brolucizumab (Beovu): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
- MHRA: EYLEA 40 mg/mL (aflibercept solution for intravitreal injection): Higher risk of intraocular pressure increase with the pre-filled syringe
- MHRA: Tumour necrosis factor alpha inhibitors
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG242: Diabetic retinopathy: management and monitoring
- NICE TA 68: Photodynamic therapy for age related macular degeneration
- NICE TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
- NICE TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion
- NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration
- NICE TA1093: Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over
- NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
- NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
- NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
- NICE TA274: Ranibizumab for treating diabetic macular oedema
- NICE TA274:Ranibizumab for treating diabetic macular oedema - updated 26/10/2023
- NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
- NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
- NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
- NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
- NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
- NICE TA346: Aflibercept for treating diabetic macular oedema
- NICE TA346: Aflibercept for treating diabetic macular oedema
- NICE TA346: Aflibercept for treating diabetic macular oedema
- NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
- NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
- NICE TA486: Aflibercept for treating choroidal neovascularisation
- NICE TA486: Aflibercept for treating choroidal neovascularisation
- NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal)
- NICE TA637: Ranibizumab for treating diabetic retinopathy (terminated appraisal)
- NICE TA672: Brolucizumab for treating wet age-related macular degeneration
- NICE TA672: Brolucizumab for treating wet age-related macular degeneration
- NICE TA799: Faricimab for treating diabetic macular oedema
- NICE TA799: Faricimab for treating diabetic macular oedema
- NICE TA800: Faricimab for treating wet age-related macular degeneration
- NICE TA800: Faricimab for treating wet age-related macular degeneration
- NICE TA820: Brolucizumab for treating diabetic macular oedema
- NICE TA820: Brolucizumab for treating diabetic macular oedema
- NICE TSID10590: High-dose aflibercept for treating wet age-related macular degeneration
- Pulsion brand SPC (may require password)